(Q53416462)

14 May 2018

title

Chronic liver disease in the extremely elderly of 80 years or more: clinical characteristics, prognosis and patient survival analysis. (English)

1 reference

14 May 2018

main subject

chronic liver disease

0 references

author name string

Hoshida Y

1

1 reference

14 May 2018

Ikeda K

2

1 reference

14 May 2018

Kobayashi M

3

1 reference

14 May 2018

Suzuki Y

4

1 reference

14 May 2018

Tsubota A

5

1 reference

14 May 2018

Saitoh S

6

1 reference

14 May 2018

Arase Y

7

1 reference

14 May 2018

Kobayashi M

8

1 reference

14 May 2018

Murashima N

9

1 reference

14 May 2018

Chayama K

10

1 reference

14 May 2018

Kumada H

11

1 reference

14 May 2018

publication date

1 November 1999

1 reference

14 May 2018

published in

Journal of Hepatology

1 reference

14 May 2018

volume

31

1 reference

14 May 2018

issue

5

1 reference

14 May 2018

page(s)

860-866

1 reference

14 May 2018

Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Liver disease in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Parenchymal liver disease in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Etiologic and pathophysiological characteristics of cirrhosis of the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Different course of acute hepatitis B in elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Hepatitis C virus infection in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Hepatitis C virus infection and related chronic liver disease in a resident elderly population: the Silea Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

High carrier rate after hepatitis B virus infection in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Non A, non B hepatitis in the aged

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

The clinical course of acute hepatitis in the elderly patient

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Treatment of Hepatitis C Virus in Elderly Persons With Interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Use of immunomodulators (thymopentine) in hepatitis B vaccine in elderly patients undergoing chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Alterations in the human immune response to the hepatitis B vaccine among the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Predominant etiologic association of hepatitis C virus with hepatocellular carcinoma compared with hepatitis B virus in elderly patients in a hepatitis B-endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

HLA-A, B, C and DR in hepatitis B virus (HBV)-related liver cirrhosis: a study of 851 elderly subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Alcoholic liver disease in the elderly: presentation and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Primary biliary cirrhosis in elderly females

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Chronic active hepatitis in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Meeting report: International Autoimmune Hepatitis Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

High prevalence of antibody to hepatitis C virus in heavy drinkers with chronic liver diseases in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Significance of antibody to hepatitis C virus in Japanese patients with viral hepatitis: relationship between anti-HCV antibody and the prognosis of non-A, non-B post-transfusion hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Anti-hepatitis C virus in the elderly: a seroepidemiological study in a home for the aged

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

Transcatheter arterial chemoembolization in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980287-6

7 January 2021

10.1016/S0168-8278(99)80287-6

Identifiers

DOI

1 reference

14 May 2018

PubMed ID

10580583

1 reference

14 May 2018